Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

B‐lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting

7 Jul 2022

Abstract excerpt

BACKGROUND: The potential loss of CD19 during targeted treatment of B cell precursor acute lymphoblastic leukemia (BCP-ALL) can hamper flow cytometric minimal residual disease (MRD) monitoring. In the current study, we present expression data for antigens that are candidates for CD19 substitution: surface CD22, CD24, CD10, and intracellular (i) CD79a. METHODS: Bone marrow samples from 519 consecutive children...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to CAR-T cell therapy research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35796438
DOI: 10.1002/cyto.b.22088

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

B‐lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targetingPMID 35796438Read ↗

CD19 negative and dim precursor B-lineage acute lymphoblastic leukemias: real-world challenges in a targeted-immunotherapy eraSemantic proximity Read ↗

CD19 negative precursor B acute lymphoblastic leukemia (B‐ALL)—Immunophenotypic challenges in diagnosis and monitoring: A study of three casesSemantic proximity Read ↗

Key Markers of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detectionSemantic proximity Read ↗

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematologySemantic proximity Read ↗

Relapse/refractory paediatric B-ALL case with CD19 - phenotype switching indicating the importance of appropriate diagnostics approach and targeted treatment adjustment – case reportSemantic proximity Read ↗

Immunophenotypic portrait of leukemia‐associated‐phenotype markers in B acute lymphoblastic leukemiaSemantic proximity Read ↗

Analysis of RBP expression and binding sites identifies PTBP1 as a regulator of CD19 expression in B-ALL.Semantic proximity Read ↗

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemiaSemantic proximity Read ↗

Molecular signature of pediatric B-ALL determines outcomes post CD19 CAR-T cell therapySemantic proximity Read ↗

Single-cell profiling of CAR-T CD19 cell phenotypes and immune system dynamics in pediatric BCP-ALLSemantic proximity Read ↗

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.